proctOR™ is a mobile-first, AI-enabled platform that brings healthcare mentors and mentees together for remote proctorship, clinical training and education across all healthcare and clinical services worldwide.
proctOR™ revolutionises Remote Proctoring / Physician to Physician / Healthcare professional Support through intelligent matching, scheduling and secure real-time communication.
Allow proctees to submit cases requiring remote support. Allow proctors to run their OR / clinical schedule within the App and offer remote mentoring.
Choose from verified profiles with ratings, specialties, experience, language options and more.
Automated matchmaking notifies qualified, available proctors based on your specific needs and filters.
Proctors manage their OR / clinical schedules and mentoring availability directly in the app.
Support across multiple languages and time zones for truly global collaboration.
Seamlessly integrates with existing smart glasses and videocam technology.
Share procedure details, timing, language and clinical requirements in minutes.
Qualified proctors are notified and can apply. You choose the best match.
Connect securely via smart glasses or video and receive expert guidance in real time.
The proctOR™ App is coming soon and will bring together mentors and clinicians worldwide for remote proctorship, clinical training and education.
Pre-register now to receive updates, launch information, and early access.
Pre-Register Now →proctOR™ GmbH is currently open to private investors and is performing a raise through our bankers UniCredit.
| Issuer | proctOR GmbH |
| Offering Size | € 100,000.00 (initial) |
| Nominal Value of Share | € 1.00 (1 / one, Euro per share) |
| Conversion – Change of Control Transaction | Conversion – Change of Control Transaction - In the event of a Change of Control Transaction, the preference A shares shall convert into shares of Common Stock and the conversion price shall equal the lesser of (i) the Voluntary Conversion Price, (ii) the Conversion Price Cap and (ii) a 30% discount to the Company's enterprise value at the time of the Change of Control Transaction divided by the Fully Diluted Capitalization (the "Change in Control Conversion Price") |